Amylyx Pharmaceuticals Inc
AMLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.26B
Close$
$2.33
89.3% downside
Current Fair Value
89.3% downsideOvervalued by 89.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.26 Billion |
|---|---|
| Enterprise Value | $2.03 Billion |
| Dividend Yield | $1.02 (-) |
| Earnings per Share | $-1.53 |
| Beta | -0.2 |
| Outstanding Shares | 110,563,360 |
Return
| Return on Equity | -54.95% |
|---|---|
| Return on Assets | -51.13% |
| Return on Invested Capital | -54.86% |
Valuation & Multiples
| P/E Ratio | -13.72 |
|---|---|
| PEG | -91.64 |
| Price to Sales | - |
| Price to Book Ratio | 10.94 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.36 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 20.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.25%▼ 119.46% |
|---|---|
| Total Invested | $24.91M▼ 98.43% |
| Investors Holding | 27▼ 154.00% |
ESG Score
No data